Provided by Tiger Trade Technology Pte. Ltd.

Halozyme Therapeutics

109.84
-0.9500-0.86%
Post-market: 109.980.1400+0.13%19:30 EDT
Volume:2.49M
Turnover:272.59M
Market Cap:12.47B
PE:32.48
High:110.64
Open:109.41
Low:107.41
Close:110.79
52wk High:116.85
52wk Low:61.23
Shares:113.50M
Float Shares:112.00M
Volume Ratio:1.16
T/O Rate:2.22%
Dividend:- -
Dividend Rate:- -
EPS(TTM):3.38
EPS(LYR):2.56
ROE:173.67%
ROA:25.49%
PB:86.85
PE(LYR):42.91

Loading ...

Halozyme (HALO) Gets a Buy from H.C. Wainwright

TIPRANKS
·
May 12

Stock Track | Halozyme Therapeutics Soars 6.91% in Pre-Market on Q1 Earnings Beat

Stock Track
·
May 12

Financial Education Initiative: Huaxia Fund's 'Financial Reading Companion' Series Explores Commodity Price Trends and HALO Trading Strategy

Deep News
·
May 12

Halozyme Therapeutics Shares Rise in Extended Trade Following Results, Last up 3.4% at $68.68

THOMSON REUTERS
·
May 12

Halozyme beats Q1 revenue estimates, sets $1 billion buyback

Reuters
·
May 12

GUIDANCE:(HALO) Halozyme Therapeutics Expects Full Year 2026 Adjusted EPS Range $7.75 - $8.25, vs. FactSet Est of $8.06

MT Newswires Live
·
May 12

Earnings Flash (HALO) Halozyme Therapeutics Posts Q1 Revenue $376.7M, vs. FactSet Est of $358.6M

MT Newswires Live
·
May 12

Earnings Flash (HALO) Halozyme Therapeutics Posts Q1 Adjusted EPS $1.60, vs. FactSet Est of $1.55

MT Newswires Live
·
May 12

Halozyme Q1 2026 net income rises 27.06% to $150 million; revenue climbs 42% to $377 million

Reuters
·
May 12

BRIEF-Halozyme Therapeutics Q1 Adjusted EPS USD 1.6 Vs. IBES Estimate USD 1.53

Reuters
·
May 12

Halozyme Therapeutics Inc - Announces $1 Bln Share Repurchase Program, to Buy Back at Least $400 Mln in 2026

THOMSON REUTERS
·
May 12

Halozyme Therapeutics Q1 Adjusted EPS USD 1.6 VS. Ibes Estimate USD 1.53

THOMSON REUTERS
·
May 12

Halozyme Therapeutics Q1 Revenue USD 376.708 Million VS. Ibes Estimate USD 359.1 Million

THOMSON REUTERS
·
May 12

U.S. Earnings Preview: After Market Close May 11

Dow Jones
·
May 12

Halozyme Therapeutics Inc expected to post earnings of $1.53 a share - Earnings Preview

Reuters
·
May 09

Halozyme shareholders approve Ernst & Young as 2026 auditor at annual meeting

Reuters
·
May 08

Halozyme announces global collaboration and license agreement with GSK

TIPRANKS
·
May 08

BRIEF-Halozyme Announces Global Collaboration And License Agreement With Gsk To Develop Subcutaneous Formulations Of Multiple Promising Oncology Targets

Reuters
·
May 07

Halozyme inks global ENHANZE licensing deal with GSK for subcutaneous oncology drugs

Reuters
·
May 07

Halozyme Therapeutics Inc - Collaboration Includes Option for Additional Future Targets

THOMSON REUTERS
·
May 07